Krewel Meuselbach GmbH Germany

Krewel Meuselbach (KM) is a medium-sized Company of German origin. Beside the German Organisation, KM is historically strong in particular in Russia/CIS countries as well as Slovakia and Poland with own organisations.

Today KM is strategically focused on OTC-products with a strong competence in phyto-pharmaceutical drugs. Inhouse R&D and innovative pharmaceutical processing results in differentiated products with clear USP’s (e.g. free of alcohol and preservatives, standardized high bioavailability).

Mr Henning Thiel
Head of Business Development 

Kyowa Kirin GmbH Germany

Mr Lodewijk Bastiaan Sibeijn
General Manager D-A-CH 

L.E.K. Consulting China

Mr Perri Dong
Consultant 

Laboratoires Bouchara Recordati France

Mr Philippe Rozo
Business Development Director 

LABORATOIRES DIEPHARMEX SA Switzerland

Mr Benjamin ROUSSELOT
Mr Benjamin ROUSSELOT
LinkedIn logo Vice President Strategy & Corporate Development 
Mr Bruce BONO
Chief Commercial Officer 

LABORATOIRES URGO HEALTHCARE France

Short Company Description:

Urgo Healthcare (Turnover of 156 M€, the Self Care Division of the privately owned URGO Group, 589 M€ / 3180 employees), has leading market positions in France and on international markets (81M€ is done on International Markets through our 22 subsidiaries and exclusive distributors).

Urgo Healthcare has a portofolio of 12 brands of which 4 are global:

  • URGO in First Aid

  • HUMEX and HUMER in Cough & Cold and Allergy

  • ALVITYL in Multivitamins

Other brands are AGAVE, ALPHREMA, MORDEX, SONODOR, NOVAFIX, SONALTO, INOTYOL and GOVITAL.

We are interested in:

Urgo Healthcare is interested in Licencing-In products (range extensions and breakthrough innovations) for its different brands to be promoted in France and its network of 80 countries.

We have the expertise in different types of regulatory status, whether OTC MA Drugs, Medical Devices, Electrical Devices, Biocides, Food Supplements or Cosmetics. We focus on self-medication products with strong clinical evidence.

We are mainly interested in the following products:

- Cough&Cold, ENT and Allergy OTC Drugs (based on chemical or natural ingredients)

- Cough&Cold, ENT and Allergy Medical Devices (based on natural ingredients)

- First aid (Ex: advanced wound care plasters, stop bleeding, burn injuries, innovative antiseptic solutions, insect bites, blisters, Filmogel Technology®)

- Pain management products (Electrotherapy devices, Creams, Gels, Hot&Cold Patches and Sport Injuries)

- Oral Care & Dental care

- Skin care (Including baby care)

- Foot care

- Veinotonic

- Gynecology care (vaginal dryness & infections, Pelvis pain, infertility …)

- Food Supplement for well being and vitality for all the family (Ex: Probiotics)

- Hearing discomfort devices (hearing loss, tinnitus …)

Website:
www.urgo.com
Mr Pascal AUZIERE
Strategic Business Development Director 
Mr Hugo METIVIER
BUSINESS DEVELOPMENT MANAGER 

LABORATORIOS RUBIO, S.A. Spain

Mr PELAYO RUBIO
CEO 
Mr Marti Monras
Business Development Manager 

Liberty Pharma France

Liberty Pharma group is a French family business specialised in the development and manufacturing of finished products, with various status, from pharmaceutical to food supplement.

We are offering a full service (MA Dossier + Supply) to partners willing to create and complement their range with products that we offer.

Among others, we are working with multinational companies such as Servier, Mylan, Teva, BMS, Sanofi, Sandoz which appreciate our full service reactivity and quality.

Liberty Pharma offers several kind of products. Our Product list, available on demand, features :
- Medical mouthwashes
- Cough and cold products : pharmaceutical, phytotherapy, medical device and also food supplement
- Gastro-enterology products : both pharmaceutical and phytotherapy
- Venous pathologies : Food supplement range
- Dermatology : Scabies treatment

Each dossier is fully developed internally and is available to be audited in our online platform. We are looking for partners interested by the MA Dossiers / finished products that we offer, with a supply full service in order to launch innovative and unique products or to complete an existing range.

Our standard business model is open to discussion but normally we sell directly MA Dossiers, to our partners, combined with a long-term supply contract.
We don't have any trademarks or sales force, nor interest in licensing-in.
Dr Maxime Hassid
Export Director 

LTS Lohmann Therapie-Systeme AG Germany

Dr Jörg Mayer
Dr Jörg Mayer
LinkedIn logo Head BD Europe 
Mrs Klaudia Haczkiewicz
Head of Business Development 

Lupin Atlantis Holdings SA Switzerland

Dr sandra single
Senior Director BD